Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort

Since 2017, two immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of metastatic urothelial carcinoma in Europe: pembrolizumab as second-line therapy and avelumab as maintenance therapy. Our aim was to describe the use of ICIs as first and later lines of treatment in patients with metastatic bladder cancer (mBC) in the Netherlands. We identified all patients diagnosed with primary mBC between 2018 and 2021 in the Netherlands from the Netherlands Cancer Registry (NCR). NCR data were supplemented with data from the Dutch nationwide Prospective Bladder Cancer I... Mehr ...

Verfasser: Anke Richters
Debbie G.J. Robbrecht
Richard P. Meijer
Antoine G. van der Heijden
Lambertus A.L.M. Kiemeney
Joan van den Bosch
Britt B.M. Suelmann
Berna C. Özdemir
Niven Mehra
Katja K.H. Aben
Dokumenttyp: Artikel
Erscheinungsdatum: 2024
Reihe/Periodikum: European Urology Open Science, Vol 59, Iss , Pp 50-54 (2024)
Verlag/Hrsg.: Elsevier
Schlagwörter: Metastatic bladder cancer / Urothelial cancer / Immune checkpoint inhibitors / Immunotherapy / Cohort study / Diseases of the genitourinary system. Urology / RC870-923 / Neoplasms. Tumors. Oncology. Including cancer and carcinogens / RC254-282
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26627033
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1016/j.euros.2023.11.010